Spore Germination as a Target for Antifungal Therapeutics
- 1 December 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (12)
Abstract
Spores are required for long-term survival of many organisms, including most fungi. For the majority of fatal human fungal pathogens, spore germination is the key process required to initiate vegetative growth and ultimately cause disease. Because germination is required for pathogenesis, the process could hold fungus-specific targets for new antifungal drug development.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (AI137409)
- Howard Hughes Medical Institute
- Hartwell Foundation
This publication has 38 references indexed in Scilit:
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western IndiaJournal of Medical Microbiology, 2011
- Spores as Infectious Propagules ofCryptococcus neoformansInfection and Immunity, 2009
- Elucidating the Pathogenesis of Spores from the Human Fungal PathogenCryptococcus neoformansInfection and Immunity, 2009
- Isolation and Characterization of Cryptococcus neoformans Spores Reveal a Critical Role for Capsule Biosynthesis Genes in Spore BiogenesisEukaryotic Cell, 2009
- Spore germination in Saccharomyces cerevisiae: global gene expression patterns and cell cycle landmarksGenome Biology, 2007
- A Controlled Trial of Aerosolized Pentamidine or Trimethoprim–Sulfamethoxazole as Primary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- BifonazoleDrugs, 1989
- Modeling of dose-response relationships.Environmental Health Perspectives, 1981
- EconazoleDrugs, 1978